Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLA Sensitivity in Burn Patients
NCT04162639Phase 4Withdrawn
- Sponsor
- Virginia Commonwealth University
- Start
- Feb 2021
- Primary completion
- Feb 2023
01
Overview
Phase 4, open-label trial (4 arms), sponsored by Virginia Commonwealth University. Primary endpoint: Change in participant's panel reactive antibody score at 12 months. Planned start Feb 2021; status: withdrawn.
Beyond the preview
Go deeper on NCT04162639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04162639.